Aminothiadiazole (NSC 4728) in patients with advanced nonsquamous carcinoma of the cervix. A phase II study of the Gynecologic Oncology Group.

Abstract

Twenty-six evaluable patients with advanced nonsquamous cell cervical cancer were treated with aminothiadiazole at a dosage of 125 mg/m2 weekly. Sixteen had received prior chemotherapy. Two patients had complete responses neither had received prior chemotherapy; nine had stable disease; 15 had increasing disease. There was a single life-threatening toxic episode. Aminothiadiazole used in this dosage and schedule has minimal activity in previously treated patients with nonsquamous cell carcinoma.

• Authors: R F Asbury, J A Blessing, P J DiSaia, J Malfetano
• Journal: American journal of clinical oncology (Am J Clin Oncol) Vol. 12 Issue 5 Pg. 375-7 (Oct 1989) ISSN: 0277-3732 [Print] United States
• PMID: 2801597 (Publication Type: Journal Article, Research Support, U.S. Gov't, P.H.S.)

Chemical References

• Antineoplastic Agents
• Thiadiazoles
• 2-amino-1,3,4-thiadiazole

Topics

• Antineoplastic Agents (adverse effects, therapeutic use)
• Carcinoma (drug therapy)
• Drug Evaluation
• Female
• Humans
• Prognosis
• Thiadiazoles (adverse effects, therapeutic use)
• Uterine Cervical Neoplasms (drug therapy)